Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 122 entries
Sorted by: Best Match Show Resources per page
Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination.

Cancers

Giraud J, Bouriez D, Seeneevassen L, Rousseau B, Sifré E, Giese A, Mégraud F, Lehours P, Dubus P, Gronnier C, Varon C.
PMID: 31010193
Cancers (Basel). 2019 Apr 19;11(4). doi: 10.3390/cancers11040560.

Gastric cancer is the third leading cause of cancer mortality worldwide. Cancer stem cells (CSC) are at the origin of tumor initiation, chemoresistance, and the formation of metastases. However, there is a lack of mouse models enabling the study...

Cite
Giraud J, Bouriez D, Seeneevassen L, et al. Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination. Cancers (Basel). 2019;11(4)doi: 10.3390/cancers11040560.
Giraud, J., Bouriez, D., Seeneevassen, L., Rousseau, B., Sifré, E., Giese, A., Mégraud, F., Lehours, P., Dubus, P., Gronnier, C., & Varon, C. (2019). Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination. Cancers, 11(4), . https://doi.org/10.3390/cancers11040560
Giraud, Julie, et al. "Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination." Cancers vol. 11,4 (2019). doi: https://doi.org/10.3390/cancers11040560
Giraud J, Bouriez D, Seeneevassen L, Rousseau B, Sifré E, Giese A, Mégraud F, Lehours P, Dubus P, Gronnier C, Varon C. Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination. Cancers (Basel). 2019 Apr 19;11(4). doi: 10.3390/cancers11040560. PMID: 31010193; PMCID: PMC6520896.
Copy Download .nbib Format: NLM
Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradation.

Bioengineering & translational medicine

Ai X, Duan Y, Zhang Q, Sun D, Fang RH, Liu-Bryan R, Gao W, Zhang L.
PMID: 33532587
Bioeng Transl Med. 2020 Sep 10;6(1):e10187. doi: 10.1002/btm2.10187. eCollection 2021 Jan.

Current drug delivery approaches for the treatment of cartilage disorders such as osteoarthritis (OA) remain inadequate to achieve sufficient drug penetration and retention in the dense cartilage matrix. Herein, we synthesize sub-30 nm lipid-polymer hybrid nanoparticles functionalized with collagen-targeting...

Cite
Ai X, Duan Y, Zhang Q, et al. Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradation. Bioeng Transl Med. 2020;6(1):e10187doi: 10.1002/btm2.10187.
Ai, X., Duan, Y., Zhang, Q., Sun, D., Fang, R. H., Liu-Bryan, R., Gao, W., & Zhang, L. (2021). Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradation. Bioengineering & translational medicine, 6(1), e10187. https://doi.org/10.1002/btm2.10187
Ai, Xiangzhao, et al. "Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradation." Bioengineering & translational medicine vol. 6,1 (2021): e10187. doi: https://doi.org/10.1002/btm2.10187
Ai X, Duan Y, Zhang Q, Sun D, Fang RH, Liu-Bryan R, Gao W, Zhang L. Cartilage-targeting ultrasmall lipid-polymer hybrid nanoparticles for the prevention of cartilage degradation. Bioeng Transl Med. 2020 Sep 10;6(1):e10187. doi: 10.1002/btm2.10187. eCollection 2021 Jan. PMID: 33532587; PMCID: PMC7823131.
Copy Download .nbib Format: NLM
Perkalite as an innovative filler for isotactic polypropylene-based nanocomposites.

Journal of nanoscience and nanotechnology

Marega C, Causin V, Marigo A, Ferrara G, Tonnaer H.
PMID: 19438024
J Nanosci Nanotechnol. 2009 Apr;9(4):2704-14. doi: 10.1166/jnn.2009.dk01.

Perkalite, an organically modified synthetic layered double hydroxide, was used as a filler in the preparation of nanocomposites based on isotactic polypropylene. The polymorphism of the polymer matrix was investigated, finding that Perkalite favors beta phase in certain conditions...

Cite
Marega C, Causin V, Marigo A, et al. Perkalite as an innovative filler for isotactic polypropylene-based nanocomposites. J Nanosci Nanotechnol. 2009;9(4):2704-14doi: 10.1166/jnn.2009.dk01.
Marega, C., Causin, V., Marigo, A., Ferrara, G., & Tonnaer, H. (2009). Perkalite as an innovative filler for isotactic polypropylene-based nanocomposites. Journal of nanoscience and nanotechnology, 9(4), 2704-14. https://doi.org/10.1166/jnn.2009.dk01
Marega, Carla, et al. "Perkalite as an innovative filler for isotactic polypropylene-based nanocomposites." Journal of nanoscience and nanotechnology vol. 9,4 (2009): 2704-14. doi: https://doi.org/10.1166/jnn.2009.dk01
Marega C, Causin V, Marigo A, Ferrara G, Tonnaer H. Perkalite as an innovative filler for isotactic polypropylene-based nanocomposites. J Nanosci Nanotechnol. 2009 Apr;9(4):2704-14. doi: 10.1166/jnn.2009.dk01. PMID: 19438024.
Copy Download .nbib Format: NLM
Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy.

Leukemia

Johnson DT, Zhou J, Kroll AV, Fang RH, Yan M, Xiao C, Chen X, Kline J, Zhang L, Zhang DE.
PMID: 34845316
Leukemia. 2021 Nov 29; doi: 10.1038/s41375-021-01432-w. Epub 2021 Nov 29.

Cancer vaccines are promising treatments to prevent relapse after chemotherapy in acute myeloid leukemia (AML) patients, particularly for those who cannot tolerate intensive consolidation therapies. Here, we report the development of an AML cell membrane-coated nanoparticle (AMCNP) vaccine platform,...

Cite
Johnson DT, Zhou J, Kroll AV, et al. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2021;doi: 10.1038/s41375-021-01432-w.
Johnson, D. T., Zhou, J., Kroll, A. V., Fang, R. H., Yan, M., Xiao, C., Chen, X., Kline, J., Zhang, L., & Zhang, D. E. (2021). Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia, . https://doi.org/10.1038/s41375-021-01432-w
Johnson, Daniel T, et al. "Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy." Leukemia vol. (2021). doi: https://doi.org/10.1038/s41375-021-01432-w
Johnson DT, Zhou J, Kroll AV, Fang RH, Yan M, Xiao C, Chen X, Kline J, Zhang L, Zhang DE. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2021 Nov 29; doi: 10.1038/s41375-021-01432-w. Epub 2021 Nov 29. PMID: 34845316.
Copy Download .nbib Format: NLM
Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs.

Science advances

Park JH, Jiang Y, Zhou J, Gong H, Mohapatra A, Heo J, Gao W, Fang RH, Zhang L.
PMID: 34134990
Sci Adv. 2021 Jun 16;7(25). doi: 10.1126/sciadv.abf7820. Print 2021 Jun.

As numerous diseases are associated with increased local inflammation, directing drugs to the inflamed sites can be a powerful therapeutic strategy. One of the common characteristics of inflamed endothelial cells is the up-regulation of vascular cell adhesion molecule-1 (VCAM-1)....

Cite
Park JH, Jiang Y, Zhou J, et al. Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. Sci Adv. 2021;7(25)doi: 10.1126/sciadv.abf7820.
Park, J. H., Jiang, Y., Zhou, J., Gong, H., Mohapatra, A., Heo, J., Gao, W., Fang, R. H., & Zhang, L. (2021). Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. Science advances, 7(25), . https://doi.org/10.1126/sciadv.abf7820
Park, Joon Ho, et al. "Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs." Science advances vol. 7,25 (2021). doi: https://doi.org/10.1126/sciadv.abf7820
Park JH, Jiang Y, Zhou J, Gong H, Mohapatra A, Heo J, Gao W, Fang RH, Zhang L. Genetically engineered cell membrane-coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs. Sci Adv. 2021 Jun 16;7(25). doi: 10.1126/sciadv.abf7820. Print 2021 Jun. PMID: 34134990; PMCID: PMC8208717.
Copy Download .nbib Format: NLM
Evaluation of a programming algorithm for deep brain stimulation in dystonia used in a double-blind, sham-controlled multicenter study.

Neurological research and practice

Steigerwald F, Kirsch AD, Kühn AA, Kupsch A, Mueller J, Eisner W, Deuschl G, Falk D, Schnitzler A, Skogseid IM, Vollmer-Haase J, Ip CW, Tronnier V, Vesper J, Naumann M, Volkmann J.
PMID: 33324891
Neurol Res Pract. 2019 Sep 24;1:25. doi: 10.1186/s42466-019-0032-2. eCollection 2019.

BACKGROUND: Programming deep brain stimulation in dystonia is difficult because of the delayed benefits and absence of evidence-based guidelines. Therefore, we evaluated the efficacy of a programming algorithm applied in a double-blind, sham-controlled multicenter study of pallidal deep brain...

Cite
Steigerwald F, Kirsch AD, Kühn AA, et al. Evaluation of a programming algorithm for deep brain stimulation in dystonia used in a double-blind, sham-controlled multicenter study. Neurol Res Pract. 2019;1:25doi: 10.1186/s42466-019-0032-2.
Steigerwald, F., Kirsch, A. D., Kühn, A. A., Kupsch, A., Mueller, J., Eisner, W., Deuschl, G., Falk, D., Schnitzler, A., Skogseid, I. M., Vollmer-Haase, J., Ip, C. W., Tronnier, V., Vesper, J., Naumann, M., Volkmann, J. (2019). Evaluation of a programming algorithm for deep brain stimulation in dystonia used in a double-blind, sham-controlled multicenter study. Neurological research and practice, 125. https://doi.org/10.1186/s42466-019-0032-2
Steigerwald, Frank, et al. "Evaluation of a programming algorithm for deep brain stimulation in dystonia used in a double-blind, sham-controlled multicenter study." Neurological research and practice vol. 1 (2019): 25. doi: https://doi.org/10.1186/s42466-019-0032-2
Steigerwald F, Kirsch AD, Kühn AA, Kupsch A, Mueller J, Eisner W, Deuschl G, Falk D, Schnitzler A, Skogseid IM, Vollmer-Haase J, Ip CW, Tronnier V, Vesper J, Naumann M, Volkmann J. Evaluation of a programming algorithm for deep brain stimulation in dystonia used in a double-blind, sham-controlled multicenter study. Neurol Res Pract. 2019 Sep 24;1:25. doi: 10.1186/s42466-019-0032-2. eCollection 2019. PMID: 33324891; PMCID: PMC7650081.
Copy Download .nbib Format: NLM
CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells.

Theranostics

Campbell GR, Zhuang J, Zhang G, Landa I, Kubiatowicz LJ, Dehaini D, Fang RH, Zhang L, Spector SA.
PMID: 34522224
Theranostics. 2021 Aug 25;11(18):9009-9021. doi: 10.7150/thno.59728. eCollection 2021.

HIV-1 is a major global health challenge. The development of an effective vaccine and a therapeutic cure are top priorities. The creation of vaccines that focus an antibody response toward a particular epitope of a protein has shown promise,...

Cite
Campbell GR, Zhuang J, Zhang G, et al. CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells. Theranostics. 2021;11(18):9009-9021doi: 10.7150/thno.59728.
Campbell, G. R., Zhuang, J., Zhang, G., Landa, I., Kubiatowicz, L. J., Dehaini, D., Fang, R. H., Zhang, L., & Spector, S. A. (2021). CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells. Theranostics, 11(18), 9009-9021. https://doi.org/10.7150/thno.59728
Campbell, Grant R, et al. "CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells." Theranostics vol. 11,18 (2021): 9009-9021. doi: https://doi.org/10.7150/thno.59728
Campbell GR, Zhuang J, Zhang G, Landa I, Kubiatowicz LJ, Dehaini D, Fang RH, Zhang L, Spector SA. CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells. Theranostics. 2021 Aug 25;11(18):9009-9021. doi: 10.7150/thno.59728. eCollection 2021. PMID: 34522224; PMCID: PMC8419049.
Copy Download .nbib Format: NLM
Binuclear C^C* Cyclometalated Platinum(II) NHC Complexes with Bridging Amidinate Ligands.

Angewandte Chemie (International ed. in English)

Leopold H, Tenne M, Tronnier A, Metz S, Münster I, Wagenblast G, Strassner T.
PMID: 27860097
Angew Chem Int Ed Engl. 2016 Dec 19;55(51):15779-15782. doi: 10.1002/anie.201607075. Epub 2016 Nov 18.

Binuclear C^C* cyclometalated NHC platinum(II) compounds with bridging amidinate ligands were synthesized to evaluate their photophysical properties. Their three-dimensional structures were determined by a combination of 2D NMR experiments, mass spectrometry, DFT calculations, and solid-state structure analysis. The bridging...

Cite
Leopold H, Tenne M, Tronnier A, et al. Binuclear C^C* Cyclometalated Platinum(II) NHC Complexes with Bridging Amidinate Ligands. Angew Chem Int Ed Engl. 2016;55(51):15779-15782doi: 10.1002/anie.201607075.
Leopold, H., Tenne, M., Tronnier, A., Metz, S., Münster, I., Wagenblast, G., & Strassner, T. (2016). Binuclear C^C* Cyclometalated Platinum(II) NHC Complexes with Bridging Amidinate Ligands. Angewandte Chemie (International ed. in English), 55(51), 15779-15782. https://doi.org/10.1002/anie.201607075
Leopold, Hendrik, et al. "Binuclear C^C* Cyclometalated Platinum(II) NHC Complexes with Bridging Amidinate Ligands." Angewandte Chemie (International ed. in English) vol. 55,51 (2016): 15779-15782. doi: https://doi.org/10.1002/anie.201607075
Leopold H, Tenne M, Tronnier A, Metz S, Münster I, Wagenblast G, Strassner T. Binuclear C^C* Cyclometalated Platinum(II) NHC Complexes with Bridging Amidinate Ligands. Angew Chem Int Ed Engl. 2016 Dec 19;55(51):15779-15782. doi: 10.1002/anie.201607075. Epub 2016 Nov 18. PMID: 27860097.
Copy Download .nbib Format: NLM
In vitro testing to assess the UVA protection performance of sun care products.

International journal of cosmetic science

, Gers-Barlag H, Klette E, Bimczok R, Springob C, Finkel P, Rudolph T, Gonzenbach HU, Schneider PH, Kockott D, Heinrich U, Tronnier H, Bernklau R, Johncock W, Langner R, Driller HJ, Westenfelder H.
PMID: 18503434
Int J Cosmet Sci. 2001 Feb;23(1):3-14. doi: 10.1046/j.1467-2494.2001.00048.x.

The UVA protection delivered by sunscreens is an issue of increasing importance due to the increasing knowledge about UVA-induced skin damage. In Europe there is no officially accepted method available to determine the degree of UVA protection. Therefore, the...

Cite
, Gers-Barlag H, Klette E, et al. In vitro testing to assess the UVA protection performance of sun care products. Int J Cosmet Sci. 2001;23(1):3-14doi: 10.1046/j.1467-2494.2001.00048.x.
, Gers-Barlag, H., Klette, E., Bimczok, R., Springob, C., Finkel, P., Rudolph, T., Gonzenbach, H. U., Schneider, P. H., Kockott, D., Heinrich, U., Tronnier, H., Bernklau, R., Johncock, W., Langner, R., Driller, H. J., & Westenfelder, H. (2001). In vitro testing to assess the UVA protection performance of sun care products. International journal of cosmetic science, 23(1), 3-14. https://doi.org/10.1046/j.1467-2494.2001.00048.x
, et al. "In vitro testing to assess the UVA protection performance of sun care products." International journal of cosmetic science vol. 23,1 (2001): 3-14. doi: https://doi.org/10.1046/j.1467-2494.2001.00048.x
, Gers-Barlag H, Klette E, Bimczok R, Springob C, Finkel P, Rudolph T, Gonzenbach HU, Schneider PH, Kockott D, Heinrich U, Tronnier H, Bernklau R, Johncock W, Langner R, Driller HJ, Westenfelder H. In vitro testing to assess the UVA protection performance of sun care products. Int J Cosmet Sci. 2001 Feb;23(1):3-14. doi: 10.1046/j.1467-2494.2001.00048.x. PMID: 18503434.
Copy Download .nbib Format: NLM
CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells.

Theranostics

Campbell GR, Zhuang J, Zhang G, Landa I, Kubiatowicz LJ, Dehaini D, Fang RH, Zhang L, Spector SA.
PMID: 34522224
Theranostics. 2021 Aug 25;11(18):9009-9021. doi: 10.7150/thno.59728. eCollection 2021.

HIV-1 is a major global health challenge. The development of an effective vaccine and a therapeutic cure are top priorities. The creation of vaccines that focus an antibody response toward a particular epitope of a protein has shown promise,...

Cite
Campbell GR, Zhuang J, Zhang G, et al. CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells. Theranostics. 2021;11(18):9009-9021doi: 10.7150/thno.59728.
Campbell, G. R., Zhuang, J., Zhang, G., Landa, I., Kubiatowicz, L. J., Dehaini, D., Fang, R. H., Zhang, L., & Spector, S. A. (2021). CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells. Theranostics, 11(18), 9009-9021. https://doi.org/10.7150/thno.59728
Campbell, Grant R, et al. "CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells." Theranostics vol. 11,18 (2021): 9009-9021. doi: https://doi.org/10.7150/thno.59728
Campbell GR, Zhuang J, Zhang G, Landa I, Kubiatowicz LJ, Dehaini D, Fang RH, Zhang L, Spector SA. CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells. Theranostics. 2021 Aug 25;11(18):9009-9021. doi: 10.7150/thno.59728. eCollection 2021. PMID: 34522224; PMCID: PMC8419049.
Copy Download .nbib Format: NLM
Pallidal stimulation: an alternative to pallidotomy?.

Neurosurgical focus

Tronnier VM, Fogel W, Kronenbuerger M, Steinvorth S.
PMID: 15096016
Neurosurg Focus. 1997 Mar 15;2(3):e10. doi: 10.3171/foc.1997.2.5.10.

A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985. Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community....

Cite
Tronnier VM, Fogel W, Kronenbuerger M, et al. Pallidal stimulation: an alternative to pallidotomy?. Neurosurg Focus. 1997;2(3):e10doi: 10.3171/foc.1997.2.5.10.
Tronnier, V. M., Fogel, W., Kronenbuerger, M., & Steinvorth, S. (1997). Pallidal stimulation: an alternative to pallidotomy?. Neurosurgical focus, 2(3), e10. https://doi.org/10.3171/foc.1997.2.5.10
Tronnier, V M, et al. "Pallidal stimulation: an alternative to pallidotomy?." Neurosurgical focus vol. 2,3 (1997): e10. doi: https://doi.org/10.3171/foc.1997.2.5.10
Tronnier VM, Fogel W, Kronenbuerger M, Steinvorth S. Pallidal stimulation: an alternative to pallidotomy?. Neurosurg Focus. 1997 Mar 15;2(3):e10. doi: 10.3171/foc.1997.2.5.10. PMID: 15096016.
Copy Download .nbib Format: NLM
S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und Diagnostik.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S.
PMID: 30615280
J Dtsch Dermatol Ges. 2019 Jan;17(1):94-104. doi: 10.1111/ddg.13733_g.

No abstract available.

Cite
Lang BM, Balermpas P, Bauer A, et al. S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und Diagnostik. J Dtsch Dermatol Ges. 2019;17(1):94-104doi: 10.1111/ddg.13733_g.
Lang, B. M., Balermpas, P., Bauer, A., Blum, A., Brölsch, G. F., Dirschka, T., Follmann, M., Frank, J., Frerich, B., Fritz, K., Hauschild, A., Heindl, L. M., Howaldt, H. P., Ihrler, S., Kakkassery, V., Klumpp, B., Krause-Bergmann, A., Löser, C., Meissner, M., Sachse, M. M., Schlaak, M., Schön, M. P., Tischendorf, L., Tronnier, M., Vordermark, D., Welzel, J., Weichenthal, M., Wiegand, S., Kaufmann, R., & Grabbe, S. (2019). S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und Diagnostik. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 17(1), 94-104. https://doi.org/10.1111/ddg.13733_g
Lang, Berenice M, et al. "S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und Diagnostik." Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG vol. 17,1 (2019): 94-104. doi: https://doi.org/10.1111/ddg.13733_g
Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und Diagnostik. J Dtsch Dermatol Ges. 2019 Jan;17(1):94-104. doi: 10.1111/ddg.13733_g. PMID: 30615280.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 122 entries